The evolution of pathogens is a major challenge in the development and effectiveness of vaccines. As pathogens mutate, they may alter the antigens that trigger immune responses, potentially rendering previously developed vaccines less effective or ineffective against new strains. This is particularly evident in rapidly evolving viruses like influenza, HIV, and SARS-CoV-2. Mutations and genetic shifts in these viruses may lead to antigenic variation, meaning that the immune system may no longer recognize the pathogen in the same way. To address this issue, scientists are employing advanced techniques such as genomic surveillance and predictive modeling to track the evolution of pathogens and anticipate new variants. By understanding these evolutionary patterns, vaccine developers can design more adaptable and broad-spectrum vaccines that remain effective even as pathogens evolve, ensuring continued protection against emerging threats.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States